Lhon Treatment: How It Works, Results and What to Expect

LHON treatment focuses on early assessment, protecting remaining vision, addressing factors that may worsen mitochondrial stress and providing visual rehabilitation. Although vision recovery varies, prompt neuro-ophthalmology care can help clarify options, monitor both eyes and support independence.

LHON treatment: what it involves

LHON treatment is a specialist-led plan for Leber hereditary optic neuropathy, an inherited mitochondrial condition that injures the optic nerve. Treatment aims to identify the cause of vision loss promptly, preserve remaining sight where possible, reduce avoidable risks and help the person adapt to changes in central vision.

There is no single treatment that reliably restores vision for every person with LHON. However, early review by a neuro-ophthalmologist is important because treatment options may be most relevant soon after symptoms begin, and other causes of optic nerve dysfunction must be excluded. Care commonly combines genetic counselling, consideration of medicine in appropriate cases, follow-up testing and low-vision rehabilitation.

LHON usually affects central vision first, making reading, recognising faces and seeing fine detail difficult. Peripheral vision often remains relatively preserved. The condition can affect one eye initially and then involve the other eye over weeks or months, although the pattern differs between individuals.

How LHON treatment works

LHON is caused by changes in mitochondrial DNA, most often involving genes that support the cell’s energy-producing system. Retinal ganglion cells, which form the optic nerve, have high energy needs. In susceptible people, mitochondrial dysfunction can contribute to loss of these cells and reduced visual signal transmission to the brain.

A specialist may discuss idebenone, an antioxidant-related medicine used in some regions for people with LHON. It is intended to support mitochondrial electron transport and may be more useful when started early in the course of vision loss. It does not work for everyone, and the expected benefit, possible side effects, treatment duration and local availability should be reviewed individually.

Supportive treatment is equally important. This includes reviewing medicines and exposures that may affect mitochondrial function, advising against smoking and excessive alcohol, managing nutritional concerns and arranging visual aids. Treatment how it is delivered depends on the timing of symptoms, genetic findings, vision tests and the person’s overall health.

Candidacy and specialist assessment

People with painless, subacute central vision loss in one or both eyes should be assessed urgently by an eye specialist. LHON is more likely when there is a family history through the maternal line, but it can occur without a known family diagnosis. Men are more often affected by visual loss, while women can carry and pass on mitochondrial variants.

Evaluation generally includes visual acuity and colour vision testing, visual-field assessment, examination of the optic nerve and optical coherence tomography (OCT), which images retinal nerve fibre layers. Blood tests or imaging may be needed to exclude inflammation, nutritional deficiency, compression of the optic nerve and other causes of optic neuropathy. Genetic testing can confirm a common LHON-associated mitochondrial variant.

Potential suitability for medicine or clinical research is assessed case by case. Factors include the genetic variant, how long symptoms have been present, the level of visual function, previous eye health and other medical conditions. A diagnosis should not be based on genetic testing alone, because some carriers never develop vision loss.

Genetic counselling can help affected people and relatives understand maternal inheritance, variable penetrance and family-planning considerations. It can also support informed testing decisions for relatives who may carry the same mitochondrial DNA variant.

What happens during treatment and follow-up

There is usually no surgical procedure for standard LHON care. The first appointment is focused on confirming the diagnosis and establishing a visual baseline. The clinician reviews the timing of vision changes, family history, smoking and alcohol exposure, current medicines, nutrition and symptoms that could suggest another neurological or eye condition.

If a medicine such as idebenone is considered, the specialist explains its intended role and arranges follow-up to monitor visual function and tolerability. Follow-up visits may include repeat visual acuity, colour vision, visual fields and OCT scans. These results help distinguish ongoing change from stability and guide rehabilitation needs.

Low-vision rehabilitation may start at any stage rather than waiting for vision to stabilise. An optometrist, occupational therapist or rehabilitation specialist can recommend magnifiers, electronic reading devices, screen settings, orientation strategies and workplace or school adaptations. These practical measures often make daily activities more manageable.

LHON research includes gene-based approaches intended to deliver a functional mitochondrial gene to retinal cells, as well as studies of mitochondrial biology and neuroprotection. Some therapies remain investigational or are available only in particular settings, so people should discuss trial eligibility and regulatory status with a qualified specialist.

Benefits, limitations and possible risks

The potential benefits of early specialist care include a clearer diagnosis, identification of reversible alternatives, timely discussion of treatment options and access to visual rehabilitation. Some people experience partial visual improvement over time, with or without treatment, while others have persistent central vision loss. It is not possible to predict an individual outcome with certainty at diagnosis.

Idebenone can cause side effects, commonly involving the digestive system, and may not be suitable for everyone. A prescribing clinician should review other medicines, health conditions and monitoring needs. People should not start supplements or stop prescribed medicines solely because of a suspected LHON diagnosis without medical advice.

Gene therapies and other emerging approaches have potential but also uncertainties. Depending on the therapy, risks may include those associated with an eye injection, inflammation, infection, retinal complications or an immune response. These treatments require careful eligibility assessment and discussion of realistic expectations.

Supportive care has low medical risk and can provide meaningful functional benefit. It does not repair damaged optic nerve fibres, but it can improve access to information, mobility, confidence and participation in work, education and social life.

What is the prognosis for LHON patients?

The prognosis for LHON patients varies considerably. Many people develop substantial loss of central vision, while side vision is often retained. Visual loss may stabilise after the active phase, but the final level of vision and the chance of improvement depend on the mitochondrial variant, age at onset, timing of care and individual biology.

Some people have spontaneous partial recovery of central vision, sometimes months or years after onset. Recovery is reported more often with certain genetic variants than others, but it cannot be assumed or promised. Regular monitoring helps document changes and supports timely adjustments to rehabilitation strategies.

LHON generally does not cause pain and does not typically affect intelligence. A small number of people with particular mitochondrial variants may have neurological or cardiac features in addition to visual loss, so the clinical team may recommend broader assessment if symptoms suggest this.

Can you regain vision after optic nerve damage?

Whether vision can return after optic nerve damage depends on the cause, severity and duration of injury. The optic nerve has limited ability to regenerate once its nerve fibres are permanently lost. For this reason, early assessment is essential whenever central vision changes suddenly or progressively.

In LHON, partial visual recovery can occur in some individuals, even after significant vision loss, but it is unpredictable. Current care aims to protect remaining function, address contributing exposures and offer therapies that may support mitochondrial function in appropriate circumstances. Rehabilitation remains valuable regardless of the amount of recovery.

New visual symptoms should never automatically be attributed to known LHON. Conditions such as optic neuritis, glaucoma, retinal disease, nutritional optic neuropathy and compression of the optic nerve may need different and sometimes urgent treatment.

How rare is LHON disease, and what can trigger it?

LHON is a rare disease. Its prevalence differs between populations and is difficult to estimate precisely because not every carrier develops symptoms and some people may remain undiagnosed. It is most commonly associated with one of three primary mitochondrial DNA variants, inherited through the mother.

Having an LHON-associated variant does not mean a person will definitely develop vision loss. Researchers believe that additional genetic, environmental and hormonal factors influence whether symptoms appear. This incomplete penetrance explains why the condition may affect some relatives but not others.

What can trigger LHON? Smoking is strongly discouraged because it is associated with increased risk in susceptible carriers. Heavy alcohol use, poor nutrition and exposure to substances or medicines that can impair mitochondrial function may also be relevant. A specialist should review any individual exposure or medication rather than advising medication changes without supervision.

A balanced diet, avoidance of tobacco and moderation or avoidance of alcohol are sensible protective measures. These steps cannot guarantee prevention, but they may reduce avoidable mitochondrial stress and support overall health.

When to seek medical care

Medical assessment should be sought urgently for new painless blurring, dimming or loss of central vision; reduced colour vision; a central blind spot; or vision changes that progress over days to weeks. The same applies when one eye is affected and the other eye begins to change. Urgent assessment helps exclude conditions that may need prompt treatment.

Emergency care is especially important if vision loss occurs with eye pain, severe headache, weakness, numbness, speech difficulty, imbalance, fever or other neurological symptoms. These features are not typical of uncomplicated LHON and require immediate evaluation.

People with confirmed LHON or an LHON-associated mitochondrial variant should arrange specialist follow-up and ask about genetic counselling. Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals diagnose and manage complex neuro-ophthalmic conditions for international patients.

Frequently asked questions

Is there a cure for LHON?

There is currently no treatment that cures LHON for every person. Care may include early specialist assessment, consideration of idebenone where appropriate, reduction of risk factors and low-vision rehabilitation. Research into gene-based and neuroprotective therapies is ongoing.

How soon should LHON treatment begin?

A person with suspected LHON should see an eye specialist urgently, ideally as soon as central vision changes are noticed. Early assessment is important to rule out other treatable conditions and discuss options that may be more relevant in recent-onset disease. The right timing and approach depend on the individual diagnosis.

Does idebenone restore vision in LHON?

Idebenone may support visual recovery or stabilisation in some people, particularly when considered early, but results are variable. It does not reliably restore vision in all patients and should only be used under specialist guidance. Follow-up testing is used to monitor vision and treatment tolerance.

Can LHON be passed on to children?

LHON-associated mitochondrial DNA is inherited through the mother. A woman who carries an associated variant can pass it to all of her children, while an affected or carrier father does not pass mitochondrial DNA to his children. Not all carriers develop visual loss, so genetic counselling is helpful for families.

Can smoking trigger LHON?

Smoking is an important avoidable risk factor for people who carry an LHON-associated mitochondrial variant. It may increase mitochondrial stress and is associated with a higher likelihood of vision loss in susceptible individuals. Stopping smoking is recommended, and support is available through healthcare professionals.

What support is available if LHON affects daily life?

Low-vision services can provide magnification tools, electronic accessibility options, mobility training and advice for work or education. Occupational therapy and counselling may also help a person adjust to visual change. Support can begin while diagnostic testing and medical follow-up continue.

References

• National Eye Institute
• American Academy of Ophthalmology
• GeneReviews
• Orphanet
• European Medicines Agency

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.